Viewray Inc (NASDAQ:VRAY) was the recipient of unusually large options trading activity on Thursday. Investors acquired 3,018 call options on the stock. This is an increase of 5,704% compared to the average volume of 52 call options.
VRAY has been the topic of several recent research reports. Mizuho reaffirmed a “buy” rating and set a $12.00 target price on shares of Viewray in a research note on Wednesday, October 25th. BidaskClub raised shares of Viewray from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Cantor Fitzgerald set a $13.00 target price on shares of Viewray and gave the stock a “buy” rating in a research note on Monday, January 8th. Finally, Northland Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Viewray in a research note on Friday, November 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $11.20.
Shares of Viewray (NASDAQ VRAY) traded down $0.36 during trading hours on Wednesday, hitting $8.93. 564,895 shares of the company’s stock were exchanged, compared to its average volume of 813,490. Viewray has a 52 week low of $4.40 and a 52 week high of $10.64. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59. The stock has a market cap of $627.48, a P/E ratio of -8.46 and a beta of 17.60.
Viewray (NASDAQ:VRAY) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.07). The business had revenue of $12.20 million for the quarter, compared to the consensus estimate of $18.63 million. The company’s quarterly revenue was up 2950.0% compared to the same quarter last year. research analysts expect that Viewray will post -1.04 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Viewray by 67.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock valued at $6,644,000 after purchasing an additional 411,866 shares during the last quarter. RTW Investments LP increased its position in shares of Viewray by 33.5% in the 3rd quarter. RTW Investments LP now owns 1,020,462 shares of the company’s stock valued at $5,878,000 after purchasing an additional 256,127 shares during the last quarter. Pura Vida Investments LLC increased its position in shares of Viewray by 132.9% in the 3rd quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock valued at $3,497,000 after purchasing an additional 346,370 shares during the last quarter. State Street Corp boosted its holdings in shares of Viewray by 631.7% in the 2nd quarter. State Street Corp now owns 395,418 shares of the company’s stock valued at $2,555,000 after buying an additional 341,376 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Viewray by 67.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 352,898 shares of the company’s stock valued at $2,033,000 after buying an additional 142,573 shares in the last quarter. 50.52% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Stock Traders Buy High Volume of Viewray Call Options (NASDAQ:VRAY)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/31/viewray-sees-unusually-large-options-volume-vray.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.